Review




Structured Review

Karius Inc karius test sequencing
Summary of enrolled plasma <t>mcfDNA-sequencing</t> studies published from 1st January 2015 to 28th February 2025. USA*: Refer to. , , , , China*: Refer to. , Germany*:Refer to.
Karius Test Sequencing, supplied by Karius Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/test+sequence/karius+spectrum/pmc12968814-148-15-15
Average 86 stars, based on 1 article reviews
karius test sequencing - by Bioz Stars, 2026-11
86/100 stars

Images

1) Product Images from "Refining the Clinical Utility of Plasma Microbial Cell-Free DNA Sequencing in High-Risk Population of Infection: A Narrative Review"

Article Title: Refining the Clinical Utility of Plasma Microbial Cell-Free DNA Sequencing in High-Risk Population of Infection: A Narrative Review

Journal: Infection and Drug Resistance

doi: 10.2147/IDR.S562107

Summary of enrolled plasma mcfDNA-sequencing studies published from 1st January 2015 to 28th February 2025. USA*: Refer to. , , , , China*: Refer to. , Germany*:Refer to.
Figure Legend Snippet: Summary of enrolled plasma mcfDNA-sequencing studies published from 1st January 2015 to 28th February 2025. USA*: Refer to. , , , , China*: Refer to. , Germany*:Refer to.

Techniques Used: Clinical Proteomics, Sequencing

The refinement strategy of clinical utility of plasma mcfDNA sequencing and prospective. *Co-mNGS Integration (Plasma + Blood Cell DNA): Cost-effectiveness should be further investigated, particularly in resource-limited settings.
Figure Legend Snippet: The refinement strategy of clinical utility of plasma mcfDNA sequencing and prospective. *Co-mNGS Integration (Plasma + Blood Cell DNA): Cost-effectiveness should be further investigated, particularly in resource-limited settings.

Techniques Used: Clinical Proteomics, Sequencing

Related Articles

Sequencing:

Article Title: Clinical efficacy of plasma cell-free dna metagenomic next-generation sequencing in diagnosing bloodstream infections.
Article Snippet: .. In 2019, a quantitative microbial cell-free DNA (cfDNA) sequencing test(the Karius Test, Karius, Inc., USA) was reported. ..

Article Title: Plasma Microbial Cell-free DNA Metagenomic Sequencing for Diagnosis of Invasive Fungal Diseases Among High-risk Outpatient and Inpatient Immunocompromised Hosts.
Article Snippet: Beatrice Z. Sim, Jordan K. Mah, Madeleine R. Heldman, Kelly L. Stanly, Kimberly E. Hanson, Angela M. Caliendo, David Andes, Luis Ostrosky-Zeichner, John R. Wingard, and Barbara D. Alexander Division of Infectious Diseases, Department of Medicine, Duke University, Durham, North Carolina, USA; Division of Infectious Diseases, Department of Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA; Section of Clinical Microbiology, Department of Pathology, University of Utah and ARUP Laboratories, Salt Lake City, Utah, USA; Division of Infectious Diseases, Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA; Division of Infectious Diseases, Department of Medicine, University of Wisconsin, Madison, Wisconsin, USA; Division of Infectious Diseases, Department of Medicine, University of Texas Medical School at Houston, Houston, Texas, USA; and Department of Medicine, University of Florida College of Medicine, Gainesville, Florida, USA

Article Title: Clinical efficacy of plasma cell-free DNA metagenomic next-generation sequencing in diagnosing bloodstream infections
Article Snippet: .. In 2019, a quantitative microbial cell-free DNA (cfDNA) sequencing test(the Karius Test, Karius, Inc., USA) was reported. ..

Article Title: Application of plasma cell-free metagenomic next-generation sequencing for the identification of Aspergillus fumigatus donor-derived infections among solid organ transplant recipients
Article Snippet: .. Plasma next-generation metagenomic sequencing (Karius test) , POD#9 , POD#13 , Aspergillus fumigatus Pseudomonas aeruginosa. ..

Article Title: Disseminated Mycobacterium intracellulare subsp. chimaera infection, undiagnosed for years, highlights the enduring clinical utility of “old school” microbiological testing and a robust differential
Article Snippet: Initial microbiological testing is recommended , ≥ 3 repeat AFB blood cultures AFB culture and histopathology on specimens from other involved body sites (tissue/fluid/abscess, explanted prosthetic material, purulent material in sternal/localized infections) AFB stains on specimens sent for culture and histopathology. .. Follow-up or second-line microbiological testing if it is accessible (guided by a clinical hypothesis and robust differential) , If cultures grow an organism identified as Mycobacterium avium-intracellulare complex, sequencing is required to confirm identification of MC species ( 16-23S ITS, rpoB, hsp65 ) Direct from sample, targeted, mycobacterial sequencing can be performed on fresh tissue/fluid (preferred) or formalin-fixed paraffin-embedded tissue (highest yield when AFB and/or noncaseating granulomas are seen on specimen) Metagenomic sequencing-based test (Karius). .. Other high-yield testing is recommended , Bone marrow biopsy if cytopenias are present Ophthalmologic examination (chorioretinal lesions are a common finding in disseminated MC infection).

Article Title: Microbial lung-to-blood translocation associates with systemic inflammation in severe pneumonia: evidence from paired plasma and lower respiratory tract metagenomics
Article Snippet: .. McfDNA sequencing (Karius Test, Karius Inc., Redwood City, CA) detects fragments of microbial DNA circulating freely in plasma. .. This non-invasive blood test identifies microbes at the species level and quantifies their abundance (reported as DNA molecules per microliter-μL).

Article Title: Refining the Clinical Utility of Plasma Microbial Cell-Free DNA Sequencing in High-Risk Population of Infection: A Narrative Review
Article Snippet: .. Christians et al developed a workflow that enriches ultrashort and rare mcfDNA fragments prior to Karius test sequencing, enabling the identification of key AMR genes, such as SCCmec, mecA, mecC, vanA, vanB, blaCTX-M , and blaKPC , with diagnostic yields ranging from 56.8% to 83.3%. ..

Article Title: Microbial Cell-Free DNA Sequencing as a Novel Diagnostic for Culture-Negative Gemella haemolysans Endocarditis.
Article Snippet: .. Owing to persistently negative blood cultures despite strong clinical suspicion, plasma microbial cell-free DNA (mcfDNA) sequencing (Karius test; Karius Inc) was performed. ..

Clinical Proteomics:

Article Title: Plasma Microbial Cell-free DNA Metagenomic Sequencing for Diagnosis of Invasive Fungal Diseases Among High-risk Outpatient and Inpatient Immunocompromised Hosts.
Article Snippet: Beatrice Z. Sim, Jordan K. Mah, Madeleine R. Heldman, Kelly L. Stanly, Kimberly E. Hanson, Angela M. Caliendo, David Andes, Luis Ostrosky-Zeichner, John R. Wingard, and Barbara D. Alexander Division of Infectious Diseases, Department of Medicine, Duke University, Durham, North Carolina, USA; Division of Infectious Diseases, Department of Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA; Section of Clinical Microbiology, Department of Pathology, University of Utah and ARUP Laboratories, Salt Lake City, Utah, USA; Division of Infectious Diseases, Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA; Division of Infectious Diseases, Department of Medicine, University of Wisconsin, Madison, Wisconsin, USA; Division of Infectious Diseases, Department of Medicine, University of Texas Medical School at Houston, Houston, Texas, USA; and Department of Medicine, University of Florida College of Medicine, Gainesville, Florida, USA

Article Title: Application of plasma cell-free metagenomic next-generation sequencing for the identification of Aspergillus fumigatus donor-derived infections among solid organ transplant recipients
Article Snippet: .. Plasma next-generation metagenomic sequencing (Karius test) , POD#9 , POD#13 , Aspergillus fumigatus Pseudomonas aeruginosa. ..

Article Title: Microbial lung-to-blood translocation associates with systemic inflammation in severe pneumonia: evidence from paired plasma and lower respiratory tract metagenomics
Article Snippet: .. McfDNA sequencing (Karius Test, Karius Inc., Redwood City, CA) detects fragments of microbial DNA circulating freely in plasma. .. This non-invasive blood test identifies microbes at the species level and quantifies their abundance (reported as DNA molecules per microliter-μL).

Article Title: Microbial Cell-Free DNA Sequencing as a Novel Diagnostic for Culture-Negative Gemella haemolysans Endocarditis.
Article Snippet: .. Owing to persistently negative blood cultures despite strong clinical suspicion, plasma microbial cell-free DNA (mcfDNA) sequencing (Karius test; Karius Inc) was performed. ..

Formalin-fixed Paraffin-Embedded:

Article Title: Disseminated Mycobacterium intracellulare subsp. chimaera infection, undiagnosed for years, highlights the enduring clinical utility of “old school” microbiological testing and a robust differential
Article Snippet: Initial microbiological testing is recommended , ≥ 3 repeat AFB blood cultures AFB culture and histopathology on specimens from other involved body sites (tissue/fluid/abscess, explanted prosthetic material, purulent material in sternal/localized infections) AFB stains on specimens sent for culture and histopathology. .. Follow-up or second-line microbiological testing if it is accessible (guided by a clinical hypothesis and robust differential) , If cultures grow an organism identified as Mycobacterium avium-intracellulare complex, sequencing is required to confirm identification of MC species ( 16-23S ITS, rpoB, hsp65 ) Direct from sample, targeted, mycobacterial sequencing can be performed on fresh tissue/fluid (preferred) or formalin-fixed paraffin-embedded tissue (highest yield when AFB and/or noncaseating granulomas are seen on specimen) Metagenomic sequencing-based test (Karius). .. Other high-yield testing is recommended , Bone marrow biopsy if cytopenias are present Ophthalmologic examination (chorioretinal lesions are a common finding in disseminated MC infection).

Ziehl-Neelsen Stain:

Article Title: Disseminated Mycobacterium intracellulare subsp. chimaera infection, undiagnosed for years, highlights the enduring clinical utility of “old school” microbiological testing and a robust differential
Article Snippet: Initial microbiological testing is recommended , ≥ 3 repeat AFB blood cultures AFB culture and histopathology on specimens from other involved body sites (tissue/fluid/abscess, explanted prosthetic material, purulent material in sternal/localized infections) AFB stains on specimens sent for culture and histopathology. .. Follow-up or second-line microbiological testing if it is accessible (guided by a clinical hypothesis and robust differential) , If cultures grow an organism identified as Mycobacterium avium-intracellulare complex, sequencing is required to confirm identification of MC species ( 16-23S ITS, rpoB, hsp65 ) Direct from sample, targeted, mycobacterial sequencing can be performed on fresh tissue/fluid (preferred) or formalin-fixed paraffin-embedded tissue (highest yield when AFB and/or noncaseating granulomas are seen on specimen) Metagenomic sequencing-based test (Karius). .. Other high-yield testing is recommended , Bone marrow biopsy if cytopenias are present Ophthalmologic examination (chorioretinal lesions are a common finding in disseminated MC infection).

Diagnostic Assay:

Article Title: Refining the Clinical Utility of Plasma Microbial Cell-Free DNA Sequencing in High-Risk Population of Infection: A Narrative Review
Article Snippet: .. Christians et al developed a workflow that enriches ultrashort and rare mcfDNA fragments prior to Karius test sequencing, enabling the identification of key AMR genes, such as SCCmec, mecA, mecC, vanA, vanB, blaCTX-M , and blaKPC , with diagnostic yields ranging from 56.8% to 83.3%. ..



Similar Products

86
Karius Inc karius test sequencing
Summary of enrolled plasma <t>mcfDNA-sequencing</t> studies published from 1st January 2015 to 28th February 2025. USA*: Refer to. , , , , China*: Refer to. , Germany*:Refer to.
Karius Test Sequencing, supplied by Karius Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/test+sequence/karius+spectrum/pmc12968814-148-15-15
Average 86 stars, based on 1 article reviews
karius test sequencing - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

86
Karius Inc metagenomic sequencing based test
Summary of enrolled plasma <t>mcfDNA-sequencing</t> studies published from 1st January 2015 to 28th February 2025. USA*: Refer to. , , , , China*: Refer to. , Germany*:Refer to.
Metagenomic Sequencing Based Test, supplied by Karius Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/test+sequence/generation+next+sequencing/pmc12955461-11-71-74
Average 86 stars, based on 1 article reviews
metagenomic sequencing based test - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

97
Foundation Medicine Inc next generation sequencing tests
Summary of enrolled plasma <t>mcfDNA-sequencing</t> studies published from 1st January 2015 to 28th February 2025. USA*: Refer to. , , , , China*: Refer to. , Germany*:Refer to.
Next Generation Sequencing Tests, supplied by Foundation Medicine Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/test+sequence/FoundationOne+Liquid+CDx/pm41686740-588-10-8
Average 97 stars, based on 1 article reviews
next generation sequencing tests - by Bioz Stars, 2026-11
97/100 stars
  Buy from Supplier

99
Psychology Software Tools test sequence
Summary of enrolled plasma <t>mcfDNA-sequencing</t> studies published from 1st January 2015 to 28th February 2025. USA*: Refer to. , , , , China*: Refer to. , Germany*:Refer to.
Test Sequence, supplied by Psychology Software Tools, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/test+sequence/E-Prime/pmc12928708-80-12-19
Average 99 stars, based on 1 article reviews
test sequence - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

86
Minitab Inc test sequence
Summary of enrolled plasma <t>mcfDNA-sequencing</t> studies published from 1st January 2015 to 28th February 2025. USA*: Refer to. , , , , China*: Refer to. , Germany*:Refer to.
Test Sequence, supplied by Minitab Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/test+sequence/sequence+test/10__1016_slash_j__wds__2026__100274-128-18-22
Average 86 stars, based on 1 article reviews
test sequence - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

86
Quest Diagnostics notch3 cadasil sequencing test
Summary of enrolled plasma <t>mcfDNA-sequencing</t> studies published from 1st January 2015 to 28th February 2025. USA*: Refer to. , , , , China*: Refer to. , Germany*:Refer to.
Notch3 Cadasil Sequencing Test, supplied by Quest Diagnostics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/test+sequence/cadasil+notch3+sequencing+test/us12496296-503-12-10
Average 86 stars, based on 1 article reviews
notch3 cadasil sequencing test - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

86
Karius Inc bal fluid mcfdna sequencing test report
Flow diagram depicting patient and sample selection for the comparison of <t>BAL</t> fluid <t>mcfDNA</t> <t>sequencing</t> with the Karius® test and standard of care testing.
Bal Fluid Mcfdna Sequencing Test Report, supplied by Karius Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/test+sequence/mcfdna+sequencing/med_rxiv__2025__11__05__25339543-51-4-28
Average 86 stars, based on 1 article reviews
bal fluid mcfdna sequencing test report - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

86
Invitae Inc next generation sequencing ngs diagnostic test
Flow diagram depicting patient and sample selection for the comparison of <t>BAL</t> fluid <t>mcfDNA</t> <t>sequencing</t> with the Karius® test and standard of care testing.
Next Generation Sequencing Ngs Diagnostic Test, supplied by Invitae Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/test+sequence/generation+next+sequencing/pmc12659938-53-10-15
Average 86 stars, based on 1 article reviews
next generation sequencing ngs diagnostic test - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

Image Search Results


Summary of enrolled plasma mcfDNA-sequencing studies published from 1st January 2015 to 28th February 2025. USA*: Refer to. , , , , China*: Refer to. , Germany*:Refer to.

Journal: Infection and Drug Resistance

Article Title: Refining the Clinical Utility of Plasma Microbial Cell-Free DNA Sequencing in High-Risk Population of Infection: A Narrative Review

doi: 10.2147/IDR.S562107

Figure Lengend Snippet: Summary of enrolled plasma mcfDNA-sequencing studies published from 1st January 2015 to 28th February 2025. USA*: Refer to. , , , , China*: Refer to. , Germany*:Refer to.

Article Snippet: Christians et al developed a workflow that enriches ultrashort and rare mcfDNA fragments prior to Karius test sequencing, enabling the identification of key AMR genes, such as SCCmec, mecA, mecC, vanA, vanB, blaCTX-M , and blaKPC , with diagnostic yields ranging from 56.8% to 83.3%.

Techniques: Clinical Proteomics, Sequencing

The refinement strategy of clinical utility of plasma mcfDNA sequencing and prospective. *Co-mNGS Integration (Plasma + Blood Cell DNA): Cost-effectiveness should be further investigated, particularly in resource-limited settings.

Journal: Infection and Drug Resistance

Article Title: Refining the Clinical Utility of Plasma Microbial Cell-Free DNA Sequencing in High-Risk Population of Infection: A Narrative Review

doi: 10.2147/IDR.S562107

Figure Lengend Snippet: The refinement strategy of clinical utility of plasma mcfDNA sequencing and prospective. *Co-mNGS Integration (Plasma + Blood Cell DNA): Cost-effectiveness should be further investigated, particularly in resource-limited settings.

Article Snippet: Christians et al developed a workflow that enriches ultrashort and rare mcfDNA fragments prior to Karius test sequencing, enabling the identification of key AMR genes, such as SCCmec, mecA, mecC, vanA, vanB, blaCTX-M , and blaKPC , with diagnostic yields ranging from 56.8% to 83.3%.

Techniques: Clinical Proteomics, Sequencing

Flow diagram depicting patient and sample selection for the comparison of BAL fluid mcfDNA sequencing with the Karius® test and standard of care testing.

Journal: medRxiv

Article Title: Microbial cell-free DNA sequencing of bronchoalveolar lavage fluid improves diagnostic yield and may add clinical utility in immunocompromised patients with severe pneumonia

doi: 10.1101/2025.11.05.25339543

Figure Lengend Snippet: Flow diagram depicting patient and sample selection for the comparison of BAL fluid mcfDNA sequencing with the Karius® test and standard of care testing.

Article Snippet: For each sample, the BAL fluid mcfDNA sequencing test report included the name of each identified organism, the number of microbial reads found for the organism, and the Karius® designation for the pathogenicity of the organism (see Definitions).

Techniques: Selection, Comparison, Sequencing

Additive diagnostic value of BAL fluid mcfDNA sequencing with the Karius® test (KT-BAL) compared to standard of care (SOC) testing in immunocompromised patients with pneumonia. A) Number of organisms across all samples identified by either SOC alone, KT-BAL alone, or both techniques, split by KT-BAL category. B) Organisms identified exclusively by KT-BAL across all samples, split by KT-BAL category.

Journal: medRxiv

Article Title: Microbial cell-free DNA sequencing of bronchoalveolar lavage fluid improves diagnostic yield and may add clinical utility in immunocompromised patients with severe pneumonia

doi: 10.1101/2025.11.05.25339543

Figure Lengend Snippet: Additive diagnostic value of BAL fluid mcfDNA sequencing with the Karius® test (KT-BAL) compared to standard of care (SOC) testing in immunocompromised patients with pneumonia. A) Number of organisms across all samples identified by either SOC alone, KT-BAL alone, or both techniques, split by KT-BAL category. B) Organisms identified exclusively by KT-BAL across all samples, split by KT-BAL category.

Article Snippet: For each sample, the BAL fluid mcfDNA sequencing test report included the name of each identified organism, the number of microbial reads found for the organism, and the Karius® designation for the pathogenicity of the organism (see Definitions).

Techniques: Diagnostic Assay, Sequencing

Patients for whom BAL fluid mcfDNA testing with the Karius® test (KT-BAL) identified Category One or Two organisms missed by standard of care (SOC) had significantly more cumulative intubation days compared to patients where KT-BAL and SOC were concordant for all Category One or Two organisms. Hospital length of stay, ICU length of stay, and ICU mortality were worse in the KT-BAL only group, but these differences were not significant (Mann-Whitney U test for continuous variables, Fisher’s exact test for mortality).

Journal: medRxiv

Article Title: Microbial cell-free DNA sequencing of bronchoalveolar lavage fluid improves diagnostic yield and may add clinical utility in immunocompromised patients with severe pneumonia

doi: 10.1101/2025.11.05.25339543

Figure Lengend Snippet: Patients for whom BAL fluid mcfDNA testing with the Karius® test (KT-BAL) identified Category One or Two organisms missed by standard of care (SOC) had significantly more cumulative intubation days compared to patients where KT-BAL and SOC were concordant for all Category One or Two organisms. Hospital length of stay, ICU length of stay, and ICU mortality were worse in the KT-BAL only group, but these differences were not significant (Mann-Whitney U test for continuous variables, Fisher’s exact test for mortality).

Article Snippet: For each sample, the BAL fluid mcfDNA sequencing test report included the name of each identified organism, the number of microbial reads found for the organism, and the Karius® designation for the pathogenicity of the organism (see Definitions).

Techniques: MANN-WHITNEY